2025-05-20-Jefferies-利奎迪亚公司（LQDA）_美国胸科学会（ATS）数据展示肺动脉高压相关间质性肺疾病（PH-ILD）概况；Yutrepia即将获批；目标价升至27美元_9页_1mb

Equity Research Summary: Liquidia Corporation (LQDA)

Rating and Target Price Update

• Rating: BUY
• Previous Target Price (PT): $20.00
• New PT: $27.00
• Upside Potential: +59% from current price of $17.02

Analyst argues that the valuation gap narrowing between LQDA (EV ~$1.4B) and existing inhalable treprostinil (Tyvaso, $1.62B EV) will occur upon Yutrepia's approval.

Key Highlights from ASCENT Data

• Efficacy:

  • Baseline 6-minute walk distance (6MWD): 302.7m → Patients treated with Yutrepia improved by 26.4m at 8 weeks.
  • Percentage improvement: 8.7% vs. nebulized Tyvaso (6.5%).

• Safety/Side Effects:

  • Median dose: 132.5 mcg QID (～equivalent to ~18 breaths of nebulized Tyvaso).
  • Cough score: Baseline 1.2 → only increased to 1.3 after 8 weeks (minimal impact).
  • Most common adverse event: Cough (45% of patients).

• Regulatory Note: PDUFA approval date is May 24, expected approval around Memorial Day (May 26).

Key Business Factors and Market View

• Market Opportunity: Growing >$1.5B market for inhaled treprostinil. Once approved, the drug is expected to enter the $200K+ annual price-point range.
• Commercial Preparedness: 50 Rep sales force and medical affairs teams are fully operational ahead of launch.
• Valuation Rationale: Expansion of PH-ILD market model includes systemic sclerosis-associated ILD (SSc-ILD). Repurchased price erosion starting in 2028.

Major Catalysts

• Primary: May 24 PDUFA approval for Yutrepia in PH-ILD and PAH.
• Secondary: Expansion into SSc-ILD pipeline and successful commercial launch.

Notable Queries from Analyst

• How will Liquidia price Yutrepia to improve accessibility?
• Strategy for incorporating diversity in the salesforce build-out.

Financial Model Update

Higher revenue growth than previously expected, leading to a reiteration of BUY rating and revised PT to $27.